The stock of Neoleukin Therapeutics Inc. (NASDAQ:NLTX) increased by $0.05 on Tuesday to finish at $0.67, up 8.17 percent. The last five days have seen an average of 533,760 shares of common stock traded. 19 times new highs were reached in the current year, with a gain of $0.1610. The average number of shares traded over the last 20 days was 452,660, while the average volume over the last 50 days totaled 303,636.
NLTX stock dropped -27.57% since last month. On 08/14/23, the company’s shares reached a one-month low of $0.6100. The stock touched a high of $1.20 on 07/17/23, after rallying from a low of $0.38 in 52 weeks. The price of NLTX stock has risen by 31.63% or $0.1610 this year, reaching a new high 19 times. Still, the stock price is down -44.17% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
NLTX stock investors should be aware that Neoleukin Therapeutics Inc. (NLTX) stock had its last reported insider trading activity 5 days ago on Aug 11. On Aug 11, Interim CFO, Prin Acct Off Smith Sean Michael sold 1,323 shares at $0.62 each. This transaction resulted in the insider making $818. On Apr 03, Patel Priti sold 3,769 shares at a price of US$0.69. After the transaction, the insider now owns 37,313 shares. Chief Medical Officer Patel Priti had earlier sold 14,380 shares on Feb 02 for $0.60 a share. The transaction was completed for $8,588.
Financial Health
For the three months ended March 30, Neoleukin Therapeutics Inc.’s quick ratio was 17.20, while its current ratio was 17.20, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $59.1 million.
Earnings Surprise
According to Neoleukin Therapeutics Inc.’s quarterly financial report for the quarter that ended March 30, it had $58.5 million in cash and short-term investments. It was predicted that Neoleukin Therapeutics Inc.’s quarterly earnings would be -$0.26, but it ended up being -$0.12, beating the consensus by -116.70%. At the end of Neoleukin Therapeutics Inc.’s most recent quarter ended March 30, its liabilities totaled 14.43 million, while its total debt was $11.04 million. Equity owned by shareholders amounts to $44.02 million.
Technical Picture
Here’s a quick look at Neoleukin Therapeutics Inc.’s (NLTX) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 50.14%, suggesting the stock is Neutral, with a 45.91% historical volatility rate.
The stochastic %K and %D were 28.16% and 16.94% respectively, while the average true range (ATR) was 0.0395. Based on the 14-day stochastic reading of 63.83%, the RSI (14) reading is 43.99%. On the 9-day MACD Oscillator, the stock is at -0.0072, and the 14-day reading is at -0.0202.
Analyst Ratings
Analysts have assigned Neoleukin Therapeutics Inc. (NLTX) an Hold rating. NLTX is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.
What is NLTX’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.50 and $1.50, with a median target price of $1.50. In analyzing these forecasts, the average price target given by analysts for Neoleukin Therapeutics Inc. (NLTX) is $1.50.
